Validation of the reflux symptom questionnaire electronic diary in partial responders to proton pump inhibitor therapy

Clinical and Translational Gastroenterology

Volumn 3, Issue , 2012, Pages

  Vakil, Nimish ^a   Björck, Karin ^b   Denison, Hans ^b   Halling, Katarina ^c   Karlsson, Maria ^b   Paty, Jean ^d   Silberg, Debra G ^e   Rydén, Anna ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c PRO Consulting   (Sweden)

^d PRO Consulting   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LESOGABERAN; PLACEBO; PROTON PUMP INHIBITOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTENT VALIDITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRONBACH ALPHA COEFFICIENT; DISCRIMINANT VALIDITY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM RATING SCALE; HUMAN; INTERNAL CONSISTENCY; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PARALLEL DESIGN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REFLUX SYMPTOM QUESTIONNAIRE ELECTRONIC DIARY; STANDARD; SYMPTOM; TEST RETEST RELIABILITY;

EID: 84861903126     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2012.1     Document Type: Article

References (32)

1. van Pinxteren B, Numans ME, Bonis PA et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2004; 4: CD002095.
2. Donnellan C, Sharma N, Preston C et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005; 4: CD003245.
3. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-737.
4. Fass R, Shapiro M, Dekel R et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005; 22: 79-94. (Pubitemid 41039696)
5. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010; 32: 334-343.
6. Lehmann A. New pharmacological concepts in the treatment of gastro-oesophageal reflux disease. Eur Gastroenterol Hepatol Rev 2010; 6: 100-103.
7. Boeckxstaens GE, Beaumont H, Mertens V et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139: 409-417.
8. Boeckxstaens GE, Rydholm H, Lei A et al. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower esophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010; 31: 1208-1217.
9. Weigt J, Monkemuller K, Peitz U et al. Multichannel intraluminal impedance and pH-metry for investigation of symptomatic gastroesophageal reflux disease. Dig Dis 2007; 25: 179-182. (Pubitemid 350194164)
10. Iwakiri K, Kawami N, Sano H et al. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring. J Gastroenterol 2009; 44: 708-712.
11. Vakil N, Veldhuyzen van Zanten S, Kahrilas P et al. The Montreal definition and classification of gastro-esophageal reflux disease (GERD)-a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-1920.
12. Food and Drug Administration##Patient-reported outcome measures: use in medical product development to support labeling claims. 2009 8 December 2009 [cited 2009 9 December]; Final guidance document]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf.
13. Shaw M, Dent J, Beebe T et al. The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008; 6: 31.
14. Shaw MJ, Talley NJ, Beebe TJ et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-57. (Pubitemid 32104807)
15. Veldhuyzen van Zanten S, Armstrong D, Barkun A et al. Symptom overlap in patients with upper gastrointestinal complaints in the Canadian confirmatory acid suppression test (CAST) study: further psychometric validation of the Reflux Disease Questionnaire. Aliment Pharmacol Ther 2007; 25: 1087-1097. (Pubitemid 46587686)
16. Wild D, Grove A, Martin M et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 2005; 8: 94-104. (Pubitemid 40525371)
17. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415. (Pubitemid 20025670)
18. Juniper EF, Guyatt GH, Willan A et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-87. (Pubitemid 24034293)
19. Guyatt GH, Osoba D, Wu AW et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383. (Pubitemid 34260746)
20. Robinson M, Sahba B, Avner D et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995; 9: 25-31.
21. Dimenäs E, Glise H, Hallerback B et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046-1052.
22. Fayers PM, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Wiley: Chichester, 2000.
23. Fleiss JL. The Design and Analysis of Clinical Experiments. Wiley Classics Library ed. Wiley: New York, 1999.
24. Armstrong D, Veldhuyzen SJ, Chung SA et al. Validation of a short questionnaire in English and French for use in patients with persistent upper gastrointestinal symptoms despite proton pump inhibitor therapy: the PASS (Proton pump inhibitor Acid Suppression Symptom) test. Can J Gastroenterol 2005; 19: 350-358. (Pubitemid 41007494)
25. Dent J, Kahrilas PJ, Vakil N et al. Clinical trial design in adult reflux disease - a methodological workshop. Aliment Pharmacol Ther 2008; 28: 107-126. (Pubitemid 351782809)
26. Vakil N. Epigastric pain in dyspepsia and reflux disease. Rev Gastroenterol Disord 2003; 3 (Suppl 4): S16-S21. (Pubitemid 37526946)
27. McColl E. Best practice in symptom assessment: a review. Gut 2004; 53 (Suppl 4): iv49-iv54. (Pubitemid 38580761)
28. Bakowsky VS, Hanly JG. Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center. J Rheumatol 1999; 26: 1557-1563. (Pubitemid 29317880)
29. Smith JA, Decalmer S, Kelsall A et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology 2010; 139: 754-762.
30. Liu JY, Woloshin S, Laycock WS et al. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med 2004; 164: 2058-2064. (Pubitemid 39390565)
31. Thompson SK, Cai W, Jamieson GG et al. Recurrent symptoms after fundoplication with a negative pH study - recurrent reflux or functional heartburn? J Gastrointest Surg 2009; 13: 54-60.
32. Bredenoord AJ, Weusten BL, Timmer R et al. Air swallowing, belching, and reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2006; 101: 1721-1726. (Pubitemid 44166577)